Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: A cohort study

Birabaharan, Morgan; Kaelber, David C.; Karris, Maile Y.

doi:10.1016/j.jaad.2021.11.025

Cited by 26 publications

(33 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Israel, Barda et al [ 25 ] also noted a 43% heightened risk of herpes zoster among BNT162b2 recipients compared to non-recipients. However, two other surveillance studies from Israel [ 37 ] and the USA [ 26 ] found no significant association between BNT162b2 and herpes zoster. Hence, the link between BNT12b2 and herpes zoster remains ambiguous ( Table 3 ).…”

Section: Resultsmentioning

confidence: 99%

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies

Yong

Halim

et al. 2022

Vaccines

View full text Add to dashboard Cite

Given the increasing anti-vaccine movements erroneously touting vaccine danger, this review has investigated the rare adverse events potentially associated with BNT162b2 (Pfizer-BioNTech), an mRNA vaccine against the severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2). Only real-world surveillance studies with at least 0.1 million BNT162b2-vaccinated participants and one unvaccinated control group were selected for review. A total of 21 studies examining the potential association of BNT162b2 with cardiovascular, herpetic, thrombotic or thrombocytopenic, neurological, mortality, and other miscellaneous rare adverse events were described in this review. Only myocarditis is consistently associated with BNT162b2. An unclear direction of association was seen with stroke (hemorrhagic and ischemic), herpes zoster, and paresthesia from BNT162b2, which may require more studies to resolve. Fortunately, most surveillance studies detected no increased risks of the remaining rare adverse events reviewed herein, further reassuring the safety of BNT162b2. In conclusion, this review has concisely summarized the current rare adverse events related and unrelated to BNT162b2, arguably for the first time in sufficient depth, to better communicate vaccine safety to the public.

show abstract

Section: Resultsmentioning

confidence: 99%

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies

Yong

Halim

et al. 2022

Vaccines

View full text Add to dashboard Cite

show abstract

“… 31 Herpes zoster has been mentioned as a possible complication of mRNA COVID-19 vaccination, but a recent study of more than one million patients vaccinated in the US showed a similar prevalence to historical cohorts. 32 During pregnancy, herpes zoster remains a rare condition with no risk associated for the mother or her infant. 33 The case of preterm birth resulted from PPROM followed by vaginal haemorrhage 48 hours later, leading to an emergency caesarean section, which is likely not secondary to the vaccine.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 mRNA vaccine in pregnancy: Results of the Swiss COVI-PREG registry, an observational prospective cohort study

Favre

Maisonneuve²,

Pomar³

et al. 2022

The Lancet Regional Health - Europe

View full text Add to dashboard Cite

“…However, they were unable to observe the difference in the relative risk of herpes zoster in the 28 days after index events within vaccinated persons compared to the control cohorts. 74 Therefore, their data suggest mRNA COVID‐19 vaccination is not associated with increased rates of VZV reactivation. However, their analysis is limited by potential misclassification bias, which is inherent in using diagnostic codes.…”

Section: Sars‐cov‐2 Infection and Vzvmentioning

confidence: 98%

SARS‐CoV‐2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?

Chen

Song

Dai

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which is the causative pathogen for the coronavirus disease 2019 (COVID‐19) pandemic, has greatly stressed our healthcare system. In addition to severe respiratory and systematic symptoms, several comorbidities increase the risk of fatal disease outcomes, including chronic viral infections. Increasing cases of lytic reactivation of human herpesviruses in COVID‐19 patients and vaccinated people have been reported recently. SARS‐CoV2 coinfection, COVID‐19 treatments, and vaccination may aggravate those herpesvirus‐associated diseases by reactivating the viruses in latently infected host cells. In this review, we summarize recent clinical findings and limited mechanistic studies regarding the relationship between SARS‐CoV‐2 and different human herpesviruses that suggest an ongoing potential threat to human health in the postpandemic era.

show abstract

Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: A cohort study

Cited by 26 publications

References 5 publications

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies

COVID-19 mRNA vaccine in pregnancy: Results of the Swiss COVI-PREG registry, an observational prospective cohort study

SARS‐CoV‐2 infection and lytic reactivation of herpesviruses: A potential threat in the postpandemic era?

Contact Info

Product

Resources

About